Bayer confirms FY24 group outlook

Bayer confirmed its Group outlook for full-year 2024. For the Crop Science Division, the company expects currency- and portfolio-adjusted sales growth and the EBITDA margin before special items to come in at the lower end of the projected ranges between minus 1 and plus 3 percent, and between 20 and 22 percent, respectively. For the Pharmaceuticals Division, Bayer has upgraded its forecast for currency- and portfolio-adjusted sales growth to between 0 and 3 percent previously: between minus 4 and 0 percent.